Story

Capricor Therapeutics Stock Soars on Oppenheimer Upgrade, Positive FDA Update

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20261 min read
Capricor Therapeutics Stock Soars on Oppenheimer Upgrade, Positive FDA Update
Text size
Background

Shares of Capricor Therapeutics (NASDAQ:CAPR) surged 15.7% in trading on Tuesday following a stock upgrade from investment bank Oppenheimer. The analyst cited positive regulatory developments from the U.S. Food and Drug Administration (FDA) regarding the company's experimental treatment for Duchenne muscular dystrophy (DMD).

Analyst Cites Clearer Path to Approval

Oppenheimer analyst Leland Gershall upgraded Capricor from 'Perform' to 'Outperform' and initiated a price target of $54 per share. The upgrade was driven by a recent FDA update on the company's drug candidate, deramiocel.

Gershall noted that the FDA's actions suggest the agency may consider an approval based on an upper limb function indication. According to the analyst, this would align with the primary endpoint of the Phase 3 trial, for which he stated that "efficacy appears less equivocal than for cardiomyopathy." The analyst expects shares will continue to rise "as the market re-evaluates deramiocel’s approval prospects."

Sample IUX Markets – In-articleAd

FDA Sets New Review Date

The FDA accepted new materials submitted by Capricor since a recent advisory committee meeting, classifying the submission as a major amendment. This action has set a new Prescription Drug User Fee Act (PDUFA) target date of November 22 for a decision on the treatment.

In a follow-up call mentioned by Oppenheimer, Capricor CEO Linda Marbán indicated the company plans to release 24-month data from its HOPE-3 open-label extension study ahead of the new PDUFA date. This data will be part of the ongoing information provided to the FDA for its review.

Read next

More on Stocks
Back to latest news

LATEST